Your search for "Kidney Disease & Hypertension" found 35 matches:
The short-chain fatty acid acetate for improving age-associated arterial dysfunction

Specific Aim: To determine the following before and after 12 weeks of oral supplementation with calcium acetate vs. placebo (calcium citrate) in healthy men and women 50+ years of age: a) Endothelium-dependent dilation, assessed as brachial artery flow-mediated dilation (FMDBA) [primary o...

Protocol #: 22-0473

A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Children and Adults with Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

Protocol #: 22-1875

Location: Childrens Hospital Colorado

Physical Activity and Autosomal Dominant Polycystic Kidney Disease

This research study is being conducted to learn more about physical activity habits in those with ADPKD....

Protocol #: 22-0072

Location: Renal Research Center

A Phase 1, Open-Label, Multicenter Study of KYV-101-001, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis

Apheresis (collection of white blood cells) followed by lymphodepletion (medications to weaken, temporarily, your immune system so that the CAR T cells can grow and work in the body, followed by single infusion of KYV-101 (the CAR T cells made specifically for your body)...

Protocol #: 22-1850

Location: Outpatient CTRC, Renal Research Center, University of Colorado Hospital

PHANTOM: Anastrozole in Patients with Pulmonary Arterial Hypertension

Protocol #: 17-0536

Location: Outpatient CTRC, University of Colorado Hospital

Aquaman: Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendoarterectomy

This is a 3 month study to see if riociguat improves RHC measurements and exercise tolerance. There are 2 study visits - one at the beginning and one at the end - during which the subject will undergo a 6 MWT as well as a resting RHC and an exercise RHC. Study drug will be uptitrated at we...

Protocol #: 17-2349

Location: Outpatient CTRC, University of Colorado Hospital

Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD

This is a 3 month study to determine if nicotinamide riboside (a B vitamin) will improve vascular function. During this study labs, vascular function, ambulatory BP, and office BP will be measured before taking the study drug (nicotinamide riboside/placebo) and again 3 months after daily ...

Protocol #: 19-0149

Location: Renal Research Center, University of Colorado Hospital

Personalized experiences to inform improved communication for patients with Life Limiting Illness

For Aim 1, this study will test: 1) the effects on quality of communication between patient and nurse, as measured by the patient, 2) the effect of the intervention on patient’s overall biopsychosocial and spiritual well-being, as measured by the PROMIS 29 profile, and 3) the effects on pa...

Protocol #: 19-1874

Location: University of Colorado Hospital

Improving Renal Outcomes Collaborative

Protocol #: 16-2190

Location: Childrens Hospital Colorado

PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

Protocol #: 19-2332

Location: Childrens Hospital Colorado

North American Pediatric Renal Trials Collaborative Studies (NAPRTCS)

Protocol #: 19-3007

Location: Childrens Hospital Colorado

CD80 as a biomarker for kidney disease

Protocol #: 13-2700

Location: Childrens Hospital Colorado

PENGUIN: PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD

Protocol #: 20-0277

Location: Childrens Hospital Colorado, Outpatient CTRC

Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease

We want to study how feasible it is to restrict eating to 8 hours a day. Both groups will participate in a group-based, behavioral dietary intervention for 1 year (initially weekly, then monthly meetings). We will also look at changes in markers in the blood and both the size of the kidn...

Protocol #: 20-1262

Location: Anschutz Health and Wellness, Brain Imaging Center (BIC), Renal Research Center, University of Colorado Hospital

Clonal hematopoiesis, mild cognitive impairment and kidney function decline.

CH is a common aging-associated biological state that predisposes to subsequent cardiovascular death, however, whether it plays a role in MCI, dementia and kidney disease progression is unknown and understanding this novel risk factor may uncover new ways to reduce the burden of cognitiv...

Protocol #: 22-0288

Location: Renal Research Center, University of Colorado Hospital

A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)

SIngle-arm, uncontrolled, multicenter, global Phase III study designed to evaluate the efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of crovalimab in patieths with aHUS....

Protocol #: 20-2595

Location: Childrens Hospital Colorado

Multicentric Carpotarsal Osteolysis (MCTO): Natural History Study

Protocol #: 21-2606

Location: Childrens Hospital Colorado

Inspiratory Muscle Strength Training for Lowering Systolic Blood Pressure in Midlife and Older Adults with Chronic Kidney Disease

Participants will be instructed in inspiratory muscle strength training (IMST) during baseline and will be evaluated during a 3 month period to see the effects of the device on systolic blood pressure. There will be a "placebo" arm. Participants will not know which arm they are in....

Protocol #: 21-3000

Location: Brain Imaging Center - BIC, University of Colorado Hospital

Effect of Alkali Therapy on Vascular and Graft Function in Kidney Transplant Recipients

Participation will last approximately 52 weeks and will include 3-7 in-person visits. Baseline, Month 6, and Month 12 visits will be held in person to assess blood vessel health. Baseline visits will be coordinated with patients' 1 year post-transplant biopsy. The Month 12 biopsy wil...

Protocol #: 21-3447

Location: Renal Research Center, University of Colorado Hospital

Identifying novel therapeutic targets in MCTO by unbiased proteomics of patient plasma

Protocol #: 21-3367

Location: Childrens Hospital Colorado, Department Specific Free Standing Clinic

A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF OBINUTUZUMAB IN ADOLESCENT PATIENTS WITH ACTIVE CLASS III OR IV LUPUS NEPHRITIS

Protocol #: 21-4110

Location: Childrens Hospital Colorado

Effects of SGLT2 inhibition on early diabetic kidney disease: interrogation of renal energetics by functional imaging and single-cell transcriptomics- an ancillary study to the ATTEMPT trial (COMIRB #19-2947)

Protocol #: 21-4373

Location: Childrens Hospital Colorado

A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy

Protocol #: 21-4569

Location: Childrens Hospital Colorado, University of Colorado Hospital

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of FInerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Patients with Non-Diabetic Chronic Kidney Disease

Trial to examine: -the impact of Finerenone vs. Placebo in delaying the progression of kidney disease. -the safety of Finerenone vs. Placebo in addition to standard of care treatment -quality of life measures via survey This trial will include 1580 participants worldwide. Stu...

Protocol #: 21-4551

Location: Renal Research Center

A PHASE III, RANDOMIZED, OPEN-LABEL ACTIVE COMPARATOR-CONTROLLED MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH PRIMARY MEMBRANOUS NEPHROPATHY

Protocol #: 21-4960

Location: Renal Research Center, University of Colorado Hospital

Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease

Participation involves taking the study drug empagliflozin or a placebo for 12 months. Blood sample collection, magnetic resonance imaging (MRI) of the kidneys and blood vessel stiffness testing during visits at baseline, 3-month and 12-month to the Renal Research Clinic located at the...

Protocol #: 22-0616

Location: Brain Imaging Center (BIC), Brain Imaging Center - BIC, Renal Research Center, University of Colorado Hospital

Molecular Mechanisms of SGLT2 inhibition in diabetic kidney disease

Protocol #: 22-0668

Location: Brain Imaging Center (BIC), Outpatient CTRC, University of Colorado Hospital

Phase 2a Randomized Placebo-Controlled Double-Blind Multicenter Trial of VIB4920 for Active Lupus Nephritis

A double-blind, placebo-controlled trial of investigational agent combined with MMF....

Protocol #: 22-0596

Location: Renal Research Center, University of Colorado Hospital

The Nephrotic Syndrome Study Network (NEPTUNE)

Collection of blood, urine and tissue (optional)...

Protocol #: 22-0895

Location: Renal Research Center, University of Colorado Hospital

Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes

Protocol #: 22-1027

Location: Outpatient CTRC, University of Colorado Hospital

DiEtary Sodium Intake effects on ertugliflozin-induced changes in GFR, reNal oxygenation and systemic hemodynamics: the DESIGN study, a randomized, placebo-controlled, cross-over study with ertugliflozin in people with type 2 diabetes

If you choose to participate, you will take the study medication, ertugliflozin, or placebo over 4 so-called treatment blocks of 20 days each. You will be recommended foods based on a sodium-controlled diet for approximately 23 weeks. There will be 5 study visits total over 23 weeks, which...

Protocol #: 22-0224

Location: Outpatient CTRC, University of Colorado Hospital

A 36-week, single-arm, open-label study to evaluate the safety and tolerability of ferric citrate in children with hyperphosphatemia related to chronic kidney disease.

A single arm trial evaluating efficacy of ferric citrate over 36 weeks in pediatric patients with hyperphosphatemia related to CKD....

Protocol #: 23-0073

Location: Childrens Hospital Colorado

Acute Equol Supplementation and Vascular Function in Postmenopausal Women with and without CKD

-One screening visit (1.5 hours) and two testing visits (each 5 hours) -Testing visits will include a blood draw and non-invasive testing of blood vessel function -All visits will take place at CU Anschutz As a volunteer, you will receive the following information about your health: ...

Protocol #: 23-0070

Location: Renal Research Center, University of Colorado Hospital

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of BION-1301 in Adults with IgA Nephropathy

The medication is taken by injection every 2 weeks for two years. ...

Protocol #: 23-0695

Location: Renal Research Center

Phenotyping Resting and Exertional Right Ventricular Dysfunction Among Patients with Chronic Obstructive Pulmonary Disease and Pulmonary Artery Enlargement

Study participants will undergo testing to identify patterns of right ventricular dysfunction. If a study participant decides to participate in exercise training, the participant will complete an optional Part 2 of the study. Optional Part 2 includes an exercise training intervention follo...

Protocol #: 23-0516

Location: CTRC Inpatient, Outpatient CTRC, University of Colorado Hospital